酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

Learn More
Folded page of a newspaper

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

酷通npv加速器-酷通vqn官网-酷通vqn永久免费版-酷通npv加速器

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis